BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev 2016;42:10-7. [PMID: 26620819 DOI: 10.1016/j.ctrv.2015.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Basavaiah G, Rent PD, Rent EG, Sullivan R, Towne M, Bak M, Sirohi B, Goel M, Shrikhande SV. Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer. J Glob Oncol 2018;4:1-9. [PMID: 30241272 DOI: 10.1200/JGO.17.00151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Vela N, Davis LE, Cheng SY, Hammad A, Liu Y, Kagedan DJ, Paszat L, Bubis LD, Earle CC, Myrehaug S, Mahar AL, Mittmann N, Coburn NG; Pancreas Cancer Population Outcomes Research Group. Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer. Ann Surg Oncol 2019;26:4193-203. [PMID: 31535303 DOI: 10.1245/s10434-019-07808-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Guo F, Li J, Qi Y, Hou J, Chen H, Jiang SW. HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation. Cancer Cell Int 2020;20:163. [PMID: 32435154 DOI: 10.1186/s12935-020-01248-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Sunagawa M, Yamaguchi J, Kokuryo T, Ebata T, Yokoyama Y, Sugawara G, Nagino M. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. Pancreatology 2017;17:782-7. [PMID: 28760494 DOI: 10.1016/j.pan.2017.07.188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Kantor O, Talamonti MS, Lutfi W, Wang C, Winchester DJ, Marsh R, Prinz RA, Baker MS. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. Surgery 2016;160:1466-76. [DOI: 10.1016/j.surg.2016.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Wang M, Chen W, Chen J, Yuan S, Hu J, Han B, Huang Y, Zhou W. Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies. Eur J Med Chem 2021;220:113487. [PMID: 33933752 DOI: 10.1016/j.ejmech.2021.113487] [Reference Citation Analysis]
7 Hou X, Yang L, Wang K, Zhou Y, Li Q, Kong F, Liu X, He J. HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3. Cancer Med 2021;10:350-64. [PMID: 33280236 DOI: 10.1002/cam4.3627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mohammad J, Dhillon H, Chikara S, Mamidi S, Sreedasyam A, Chittem K, Orr M, Wilkinson JC, Reindl KM. Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models. Oncotarget 2018;9:10457-69. [PMID: 29535819 DOI: 10.18632/oncotarget.23623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
9 Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Critical Reviews in Oncology/Hematology 2017;114:139-52. [DOI: 10.1016/j.critrevonc.2017.03.026] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 22.3] [Reference Citation Analysis]
10 Yonemori K, Seki N, Idichi T, Kurahara H, Osako Y, Koshizuka K, Arai T, Okato A, Kita Y, Arigami T, Mataki Y, Kijima Y, Maemura K, Natsugoe S. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Oncotarget 2017;8:70097-115. [PMID: 29050264 DOI: 10.18632/oncotarget.19591] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
11 Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2017;111:152-165. [PMID: 28259290 DOI: 10.1016/j.critrevonc.2017.01.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
12 Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer 2019;125:57-67. [PMID: 30457666 DOI: 10.1002/cncr.31787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]